Business Context and Reporting Period
Cognition Therapeutics, Inc. (CGTX), an emerging growth company incorporated in Delaware, filed this Form 8-K on December 16, 2025, reporting events occurring on December 18, 2025. The company is a biopharmaceutical entity focused on developing treatments for neurological disorders.
Key Financial Metrics
This filing is a Current Report regarding corporate actions and does not contain financial statements, revenue, profit, cash flow, or margin data. The filing details the following capital market activities:
- New ATM Program: Entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $75,000,000 of common stock.
- Commission: The company will pay Jefferies a commission of 3.0% on gross sales proceeds.
- Previous Program Termination: Terminated a prior sales agreement with B. Riley Securities, Inc., under which approximately $12,500,000 of shares remained available for sale.
Material Changes
The primary material change is the replacement of the company's equity financing mechanism. The company terminated its 2022 ATM Program with B. Riley and Cantor Fitzgerald, effective December 18, 2025, with no termination penalties. Simultaneously, the company initiated a new, larger ATM Offering with Jefferies LLC, increasing the potential capital raise capacity from the remaining $12.5 million under the old agreement to $75 million under the new agreement.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or management commentary on business performance. Key contingencies and risks noted include:
- Uncertainty of Issuance: The company cannot provide assurance that it will issue any shares under the new Sales Agreement.
- Market Conditions: Sales will be conducted based on market conditions and company instructions regarding price, time, and size limits.
- Legal Compliance: The report explicitly states it does not constitute an offer to sell shares in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the exact terms of the new Sales Agreement with Jefferies LLC in the attached Exhibit 1.2 of the Registration Statement.
- Confirm the current cash position and burn rate to assess the necessity of the new $75 million ATM facility.
- Review the prospectus supplement filed on December 18, 2025, for details on the registration statement (Form S-3).
- Monitor future filings for actual share issuances and proceeds generated under the new ATM program.